Beyond Boston: Unlikely cities stake biotech claims

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

By Alexandra Pecci • July 6, 2026

Doctor-turned-dealmaker reveals his M&A playbook

Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its oncology drugs.

By Kelly Bilodeau • July 1, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.

Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the largest capital raises so far this year.

By Kelly Bilodeau • June 30, 2026

3 late-stage MASH drugs that could rival Rezdiffra

The red-hot market has plenty of room for additional therapies from big name players and clinical stage companies alike.

By Alexandra Pecci • June 29, 2026

BIO 2026: Where pharma leaders say AI hasn’t delivered

AI hasn’t always been what it was cracked up to be in pharma. Here’s where execs say the technology hasn’t lived up to the hype.

By Meagan Parrish • June 26, 2026

A ‘nightmare bacteria’ is surging while investment in antibiotics lags

Experts are sounding the alarm about the rise in drug-resistant superbugs and urging more action.

By Kelly Bilodeau • June 25, 2026

HHS, responding to China’s rise, moves to fast-track early drug research

A series of newly planned reforms are designed to entice companies to start early trials in the U.S. rather than overseas.

By Jonathan Gardner • June 24, 2026

Backed by Sanofi and Roche, Orano Med chases radiopharma leadership

Orano Med’s industrial platform offers “unlimited” and unique access to the cancer-fighting alpha emitter lead-212.

By Alexandra Pecci • June 22, 2026

A new Westlake-backed biotech takes aim at migraines

Vedana Therapeutics recently emerged from stealth with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention.

By Jacob Bell • June 18, 2026

Why ivermectin is in the limelight again

As patient interest rises for using the antiparasitic drug in cancer, it's having an impact on R&D in the space.

By Kelly Bilodeau • June 17, 2026

Corvus CEO thinks his next blockbuster is an ITK inhibitor

It’s like “Rituxan all over again,” said CEO Richard Miller, who believes Corvus’ lead candidate could make an impact in both cancer and autoimmune diseases.

By Alexandra Pecci • June 16, 2026

How Lilly is defending its GLP empire

Eli Lilly's recent GLP-2 deal with Hanmi Pharm is another step in the drugmaker’s quest to grow its GLP franchise beyond weight loss and deepen its push into gastrointestinal disease.

By Alivia Kaylor • June 16, 2026

Astellas taps AI to reshape clinical programs as rising stars emerge

As it prepares to compete in the KRAS arena, the Japanese pharma has retooled its approach to clinical development.

By Meagan Parrish • June 12, 2026

Competition is brewing between ADCs and bispecifics

The dueling modalities are each gaining traction in lung cancer. But will they ultimately become allies?

By Kelly Bilodeau • June 11, 2026

With a promising MASH asset, muscle-sparing GLP-1 and new CEO, Rivus gets ready to make its mark

Rivus Pharmaceuticals’ CEO Jorge Bartolome said the biotech is on track to build a “truly differentiated” cardiometabolic portfolio.

By Alexandra Pecci • June 9, 2026

Will obesity drugs save Pfizer from its post-COVID slump?

With COVID’s windfall over and blockbuster patents expiring, Pfizer is looking for a comeback with its newly built obesity pipeline.

By Alivia Kaylor • June 9, 2026

3 potential takeover targets in obesity

Momentum is building to bring a next-generation weight loss drug to market, which could set up these three biotechs to strike a deal with a larger pharma.

By Kelly Bilodeau • June 8, 2026

BMS under pressure in schizophrenia; Summit/Akeso on a winning streak

While the large pharma’s new drug Cobenfy has stumbled in schizophrenia, it could find new life in Alzheimer’s disease

By PharmaVoice staff • June 5, 2026

GSK, Takeda and others notch key clinical wins in tough-to-treat diseases

From hepatitis B to melanoma, recent study results show innovative approaches are gaining ground.

By Kelly Bilodeau • June 5, 2026

Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?

While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.

By Kelly Bilodeau • June 4, 2026

When the ISS comes down, will its drug R&D be lost in space?

 As NASA prepares to bring its hallmark space lab back to Earth, a host of private companies are emerging to fill the gap.

By Meagan Parrish • June 3, 2026

As amyloid falls out of favor, here’s where Alzheimer’s R&D is headed next

The Alzheimer’s pipeline is growing as drug developers put more emphasis on inflammation, tau and biomarkers.

By Kelly Bilodeau • June 2, 2026

AstraZeneca aims for a new blockbuster run in cardio disease

With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight management and beyond, according to a company exec.

By Alexandra Pecci • June 1, 2026

Can AI crack pharma’s drug repurposing goldmine?

With AI now capable of analyzing decades’ worth of data, FDA is pushing pharma to leverage its “enormous, untapped value” by repurposing drugs.

By Alivia Kaylor • May 29, 2026

Longevity science picks up steam in pharma

Fueled by multi-billion-dollar valuations and a deeper understanding of aging biology, the field is rapidly moving past the hype and into the clinic.

By Kelly Bilodeau • May 29, 2026